



29 November 2005

Sinclair Pharma plc

Institutional placing raises approximately £7.4 million

Sinclair Pharma plc (LSE: SPH) ("Sinclair" or the "Company"), the specialty pharmaceuticals company, today announces that it has raised approximately £7.4 million before expenses through a placing for cash of 5,922,565 new Ordinary Shares of 1 pence each. The new shares, which represent approximately 10 per cent. of the Company's issued share capital prior to the placing, have been placed with new and existing institutional investors in the UK and Continental Europe, at a placing price of 125 pence per share. The placing price represents a discount of approximately 7 per cent. to the closing middle market price on the London Stock Exchange's AIM market on Monday, 28 November 2005.

Sinclair is actively pursuing acquisition opportunities to further strengthen its existing specialty pharmaceutical salesforce and product portfolio. The net proceeds of the placing will provide the Company with additional flexibility to make selective and timely acquisitions as opportunities arise.

This placing was undertaken pursuant to a resolution of the shareholders at the Company's Annual General Meeting on 28 November 2005 which approved the disapplication of shareholders' pre-emption rights in relation to issues for cash consideration of up to 5,922,565 shares (being equivalent to 10 per cent. of the then issued share capital of the Company).

Application will be made today for the new shares to be admitted and to trade on the London Stock Exchange's AIM market. The placing is conditional on admission, which is expected to become effective on 1 December 2005. When issued, the new shares will rank *pari passu* in all respects with the Company's existing ordinary shares. Following the placing, Sinclair will have a total of 65,198,219 Ordinary Shares of 1 pence each in issue.

Commenting on the placing, Dr Michael Flynn, Chief Executive Officer of Sinclair, said, "We are delighted with the strong support shown in this placing by the existing, and a number of new, institutional investors, which is built on the back of excellent progress Sinclair has made this year. These funds will provide more flexibility in our cash position as we actively look to strengthen Sinclair's European sales capabilities and on-market products through targeted acquisition."

- Ends -



Enquiries:

Sinclair Pharma plc

Michael Flynn, Chief Executive Officer
Jerry Randall, Chief Financial Officer

Tel: 01483 426644

Financial Dynamics

Ben Atwell

Tel: 020 7831 3113

Piper Jaffray Ltd.

Jamie Adams / Will Carnwath

Tel: 020 7743 8700

Further information on Sinclair can be found on the company's website:
www.sinclairpharma.com